Benzinga | Dec 9, 2020 08:37AM EST

Lantheus Holdings Announces Collaboration With POINT BiopharmaTo Use Lantheus' PSMA-Targeted Prostate Cancer Imaging Agent In PSMA-Targeted Radioligand Therapeutic Phase 3 Trial In Patients With Metastatic Castration Resistant Prostate Cancer

Lantheus Holdings, Inc. (NASDAQ:LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it has entered into a strategic collaboration with POINT Biopharma, Inc. (POINT) to use Lantheus' investigational prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent, PyL, to determine PSMA-avidity during patient selection in POINT's Phase 3 clinical trial to treat metastatic castration resistant prostate cancer (mCRPC). The collaboration directly aligns with an important Lantheus strategy to advance cancer precision medicine by enabling partners to use PyL in prostate cancer therapeutic trials.

As part of the agreement with POINT, Lantheus' subsidiary, Progenics Pharmaceuticals, Inc., will supply PyL at a predetermined supply price.

"While there have been great advances in the treatment of prostate cancer, there remains an important unmet medical need for therapies that can more specifically target metastatic prostate cancer," said Mary Anne Heino, President and Chief Executive Officer of Lantheus. "The inclusion of PyL in POINT's Phase 3 trial reinforces our belief in the potential utility of PyL, not just in assessing metastatic disease, but also in selecting the most appropriate patients for PSMA-targeted therapy."

POINT will conduct a Phase 3, multicenter, open-label, randomized clinical trial to evaluate the efficacy and safety of their novel PSMA-targeted radioligand, 177Lu-PNT2002, in patients with mCRPC. PyL will be used to select patients with PSMA-avid tumors for treatment with 177Lu-PNT2002, and in a subset of patients also be used to evaluate progression.

"The combination of diagnostic imaging and radioligand therapy is a validated approach and an important development in cancer treatment," said Joe McCann, Chief Executive Officer of POINT. "POINT is very excited to be enrolling our study using PyL. We believe this promising biomarker will help identify the patients with prostate cancer who will best respond to PNT 2002, our next generation radioligand therapy."